Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | CCR8 | P51685 | 4/20 | 0.62 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17055908 | 0.94 | KDM4E (0.65) | KDM4ECCR8ACKR3MEN1KMT2A | |
| SCHEMBL17055968 | 0.94 | KDM4E (0.65) | KDM4ECCR8ACKR3GAAPOLB | |
| SCHEMBL17055776 | 0.94 | KDM4E (0.65) | KDM4ECCR8ACKR3KMT2AGAA | |
| SCHEMBL17055885 | 0.94 | KDM4E (0.69) | KDM4ECCR8ACKR3MEN1KMT2A | |
| SCHEMBL17056010 | 0.93 | KDM4E (0.66) | KDM4ECCR8ACKR3MEN1KMT2A | |
| SCHEMBL17055899 | 0.93 | KDM4E (0.66) | KDM4ECCR8ACKR3KMT2AGAA | |
| SCHEMBL17055884 | 0.93 | KDM4E (0.66) | KDM4ECCR8ACKR3MEN1KMT2A | |
| SCHEMBL17055950 | 0.93 | KDM4E (0.68) | KDM4ECCR8ACKR3MEN1KMT2A | |
| SCHEMBL17056008 | 0.92 | KDM4E (0.65) | KDM4ECCR8ACKR3MEN1KMT2A | |
| SCHEMBL17055910 | 0.92 | KDM4E (0.65) | KDM4ECCR8ACKR3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274657-A1 | PYRROLIDINES | MERCK PATENT GMBH (DE) | 2015-10-01 | — | — | US | disclosed |
| US-20150274657-A1 | PYRROLIDINES | MERCK PATENT GMBH (DE) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274657-A1 | PYRROLIDINES | NR4A3, NR0B1, NR0B2 | KDM4E 2503/4885CCR8 1120/4885ACKR3 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.